HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Sotalol

HCID 5253
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
3930-20-9
Standard SMILES
CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1
InChIKey
ZBMZVLHSJCTVON-UHFFFAOYSA-N
Molecular formula
C12H20N2O3S
Average molar mass
272.37 g/mol
Monoisotopic mass
272.11946368

Overview

Sotalol is a sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias. It has a role as a beta-adrenergic antagonist, a xenobiotic, an anti-arrhythmia drug and an environmental contaminant. It is a member of ethanolamines, a sulfonamide, a secondary alcohol and a secondary amino compound. It is a conjugate base of a sotalol(1+).

Names & identifiers

Preferred name
Sotalol
IUPAC
N-[4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide
English name
Sotalol
Molecular formula
C12H20N2O3S
Molecular weight
272.36

Names & synonyms

sotalol3930-20-9beta-CardoneDL-SotalolSotalolumDarob miteDTXSID00235894'-(1-Hydroxy-2-(isopropylamino)ethyl)methane sulfonanilideMethanesulfonanilide, 4'-(1-hydroxy-2-(isopropylamino)ethyl)-C07AA07A6D97U294IN-(4-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}phenyl)methanesulfonamide
Show more names
SORBITOLSotalol (base and/or unspecified salts)SotololBetacotdoneAURORA KA-855Sotalol USP/EP/BPSotalol Intermediate
Methanesulfonamide, N-(4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)phenyl)-DTXCID303589CHEBI:63622Methanesulfonamide, N-[4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]phenyl]-SotaloloN-(4-(1-hydroxy-2-((propan-2-yl)amino)ethyl)phenyl)methanesulfonamideRefChem:56607MJ1999

Database identifiers

CAS
3930-20-9
PubChem CID
5253
DTXSID

Properties

Computed structural properties

XLogP
0.2
Topological polar surface area
86.8 Ų
Hydrogen bond donors
3
Hydrogen bond acceptors
5
Rotatable bonds
6
Heavy atoms
18
Formal charge
0
Complexity
330

Experimental & physicochemical properties

Drugs · 2 items

Pharmaceuticals

Pharmaceuticals -> Used in Switzerland

LogP · 2 items

1.1

0.53

Solubility7.82e-01 g/L
Human Drugs · 2 items

Breast Feeding; Lactation; Milk, Human; Antihypertensive Agents; Adrenergic Beta-Antagonists; Antiarrhythmics

Pharmaceuticals

Melting Point206.5 - 207 °C
Physical DescriptionSolid
Dissociation Constants9.76
Collision Cross Section167 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

Physicochemical properties

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]

P203, P260, P263, P264, P264+P265, P270, P280, P302+P352, P305+P351+P338, P318, P319, P321, P332+P317, P337+P317, P362+P364, and P501 (click each P-code to see the statement)

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

Hazard information

Hazard Classes and CategoriesSkin Irrit. 2 (100%)

Toxicology

Hepatotoxicity · 1 item

Mild-to-moderate elevations in serum aminotransferase levels occur in less than 2% of patients on sotalol and are usually transient and asymptomatic, resolving even with continuation of therapy. Sotalol has been linked to a single case of clinically apparent liver injury, with onset of an acute hepatitis-like syndrome with prolonged jaundice 12 weeks after sotalol was initiated. The injury improved but did not resolve with discontinuation of sotalol. In large case series of drug induced liver disease and acute liver failure, sotalol has not been listed as a cause. Other beta-blockers have been linked to rare instances of acute clinically apparent liver injury with a latency to onset ranging from 4 to 24 weeks, a hepatocellular pattern of serum enzyme elevations and a mild, self-limiting course without evidence of hypersensitivity or autoimmune reactions.

Adverse Effects · 1 item

Sotalol's adverse effect profile is inherent in the mechanisms of action as both a potassium channel blocker and a non-cardioselective β-blocker. The potassium channel blockade, primarily in phase 3 of the cardiac action potential, prolongs the QTc. Thus, the electrocardiogram (ECG) must be monitored upon initiating sotalol or adding other QTc-prolonging medications. Prolongation of the QT interval occurs in 1% to 2% of cases, which could lead to torsades de pointes or new ventricular tachycardia/ventricular fibrillation.

Chemistry & industry

Pharmacology

ATC Code · 3 items

C07AA07

C - Cardiovascular system

QC - Cardiovascular system

Protein Binding0%.
Pharmacodynamics · 1 item

Sotalol is a competitive inhibitor of the rapid potassium channel. This inhibition lengthens the duration of action potentials and the refractory period in the atria and ventricles. The inhibition of rapid potassium channels is increases as heart rate decreases, which is why adverse effects like torsades de points is more likely to be seen at lower heart rates. L-sotalol also has beta adrenergic receptor blocking activity seen above plasma concentrations of 800ng/L. The beta blocking ability of sotalol further prolongs action potentials. D-sotalol does not have beta blocking activity but also reduces a patient's heart rate while standing or exercising. These actions combine to produce a negative inotropic effect that reduces the strength of contractility of muscle cells in the heart. Extension of the QT interval is also adversely associated with the induction of arrhythmia in patients. Hyperglycemia is a greater risk for non insulin dependant diabetics than insulin dependant diabetics. Beta blockers inhibit insulin secretion which may cause hyperglycemia in type II diabetes mellitus. The risk of hypoglycemia is higher in insulin dependant diabetes than non insulin dependant diabetics. Beta blockers decrease secretion of insulin, which may mask hypoglycemia in an insulin dependant patient. Beta blockers also increase glucose uptake into cells which may prolong or potentiate hypoglycemia. Further information regarding adverse reactions can be found here.

Mechanism of Action · 1 item

Sotalol inhibits beta-1 adrenoceptors in the myocardium as well as rapid potassium channels to slow repolarization, lengthen the QT interval, and slow and shorten conduction of action potentials through the atria. The action of sotalol on beta adrenergic receptors lengthens the sinus node cycle, conduction time through the atrioventricular node, refractory period, and duration of action potentials.

Biological Half-Life · 1 item

The terminal elimination half life is 10-20 hours in healthy patients. In patients with a creatinine clearance >80mL/min, the half life is 17.5±0.97h. In patients with a creatinine clearance 30-80mL/min, the half life is 22.7±6.4h. In patients with a creatinine clearance 10-30mL/min, the half life is 64±27.2h. In patients with a creatinine clearance <10mL/min, the half life is 97.9±57.3h.

Related reactions

5 records
New reaction record
HRID 479264 reaction equation
HRID 479264As product
HRID 651495 reaction equation
HRID 651495As product
HRID 651496 reaction equation
HRID 651496As product
HRID 1534563 reaction equation
HRID 1534563As product
HRID 2301241 reaction equation
HRID 2301241As product

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
DTXSID0023589
ChEMBL
CHEMBL471
ChEBI
CHEBI:63622
UNII
A6D97U294I
EC Number
977-025-7
Nikkaji
J10.583J
Melting point
206.5 · 206.5-207 °C
Boiling point
443.3 · 443.3±55.0 °C(Predicted)
Density
1.298 g/cm3 · 1.298 g/cm3
storage temp.
-20 °C · Hygroscopic, -20°C Freezer, Under inert atmosphere
solubility
Chloroform (Slightly, Heated), Methanol (Slightly, Sonicated)
form
Solid
pka
1 · pK1 8.2, pK2 9.8(at 25℃)
color
Pale Yellow to Light Yellow
BCS Class
1 · 1
Stability
Hygroscopic
InChI
InChI=1S/C12H20N2O3S/c1-9(2)13-8-12(15)10-4-6-11(7-5-10)14-18(3,16)17/h4-7,9,12-15H,8H2,1-3H3
InChIKey
ZBMZVLHSJCTVON-UHFFFAOYSA-N
SMILES
CS(NC1=CC=C(C(O)CNC(C)C)C=C1)(=O)=O
CAS DataBase Reference
3930 · 3930-20-9(CAS DataBase Reference)
EWG's Food Scores
1 · 1
FDA UNII
6 D97U294I · A6D97U294I
ATC code
7 AA07 · C07AA07
NIST Chemistry Reference
4 · Methanesulfonanilide, 4'-(1-hydroxy-2-(isopropylamino)ethyl)-(3930-20-9)
EPA Substance Registry System
4 · Methanesulfonamide, N-[4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]phenyl]- (3930-20-9)
Symbol(GHS)
7 · GHS07
Signal word
Warning
Hazard statements
319 · H319
Precautionary statements
305 · P305+P351+P338
Hazard Codes
Xi
Risk Statements
36 · 36/37/38
Safety Statements
26 · 26-36
Toxicity Summary · 1 item

Sotalol toxicity is inherent due to the mechanism of action as both a potassium channel blocker and a non-cardioselective β-blocker and mirrors the adverse effect profile. The most obvious and potentially problematic sign of toxicity is concentration-related QTc prolongation. If QTc is over 500 ms during initiation, the sotalol dose should be reduced or discontinued. If QTc exceeds 520 ms during the maintenance phase of dosing, the clinician should either reduce the dose or discontinue sotalol.

Drug Induced Liver Injury · 5 items

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

sotalol

DILI Negative

Oral

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
EPA Human Health Benchmarks for Pharmaceuticals · 6 items

Sotalol

1.9

7.9

The starting dose of sotalol hydrochloride tablets (AF) is 80 mg twice daily (b.i.d.) if the creatinine clearance is > 60 mL/min, and 80 mg once daily (q.d.) or 40 mg twice daily (b.i.d) if the creatinine clearance is 40 to 60 mL/min.

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 80 mg/day, Lowest Therapeutic Dose (LTD): 1.0 mg/kg-day, and Screening Dose: 0.0003 mg/kg-day.

22-Jan-07

Safety data

risk_code
36/37/38
Signal word
Warning
Symbol(GHS)
GHS07
hazard_code
Xi
safety_code
26-36
Hazard statements
H319
Precautionary statements
P305+P351+P338
Metabolism/MetabolitesSotalol is not metabolized.
FDA Pharmacological Classification · 6 items

A6D97U294I

SOTALOL

Established Pharmacologic Class [EPC] - Antiarrhythmic

Physiologic Effects [PE] - Cardiac Rhythm Alteration

Mechanisms of Action [MoA] - Adrenergic beta-Antagonists

Sotalol is an Antiarrhythmic. The mechanism of action of sotalol is as an Adrenergic beta-Antagonist. The physiologic effect of sotalol is by means of Cardiac Rhythm Alteration.

MeSH Pharmacological Classification · 3 items

Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.

Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.

Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here.

Absorption, Distribution and Excretion · 4 items

Sotalol is 90-100% bioavailable. When taken with a meal, adsorption is lowered by 18%. In patients with a creatinine clearance >80mL/min, the maximum concentration is 6.25±2.19.

80-90% of a given dose is excreted in the urine as unchanged sotalol. A small fraction of the doses is excreted in the feces as unchanged sotalol.

The apparent volume of distribution is 1.2-2.4L/kg.

In patients with a creatinine clearance >80mL/min, the plasma clearance is 6.78±2.72L/h and the renal clearance is 4.99±1.43L/h. In patients with a creatinine clearance 30-80mL/min, the plasma clearance is 2.74±0.53L/h and the renal clearance is 2.00±0.67L/h. In patients with a creatinine clearance 10-30mL/min, the plasma clearance is 1.56±0.44L/h and the renal clearance is 0.65±0.31L/h. In patients with a creatinine clearance <10mL/min, the plasma clearance is 0.65±0.20L/h and the renal clearance is 0.27±0.13L/h.

Cellular LocationsMembrane
Metabolite PathwaysSotalol Action Pathway

Uses & manufacturing

UsesUse (kg) in Switzerland (2009): >250
Use ClassificationPharmaceuticals
Applications · 1 item

General DescriptionSotalol, 4'[1-hydroxy-2-(isopropylamino)ethyl]methylsulfonanilide (Betapace), is a relatively new antiarrhythmicdrug, characterized most often as a class IIIagent, and although it has effects that are related to the classII agents, it is not therapeutically considered a class II antiarrhythmic.It contains a chiral center and is marketed as theracemic mixture. Because of its enantiomers, its mechanismof action spans two of the antiarrhythmic drug classes. Thel(-) enantiomer has both β-blocking (class II) and potassiumchannel-blocking (class III) activities. The d(+) enantiomerhas class III properties similar to those of the (-) isomer,but its affinity for the -adrenergic receptor is 30 to 60 timeslower.

Upstream & downstream products

Upstream raw materials

Hydrochloric acid
Additional notes · 1 item

DefinitionChEBI: A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is sustituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and ardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.